Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Simcere Pharmaceuticals: Dr H Ming Pang, Head of International Business




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Simcere Pharmaceuticals: Dr H Ming Pang, Head of International Business
Released on: October 01, 2006. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Dr Pang talks to Fintan Walton about biotechnology trends in China.
  • Summary
  • Transcript
  • Participants
  • Company
Dr Pang talks to Fintan Walton about biotechnology trends in China. He examines what the Chinese pharmaceutical and biotechnology industry has to offer the global market, discusses the opportunities in China and presents his thoughts on the challenges that this region faces. The discussion provides an in-depth analysis and informative overview of this emergent territory, which has lately been the subject of much attention.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Dr H Ming Pang obtained his Bachelor's degree and Doctorate in the UK, and is a well-established and key opinion leader in the Chinese pharmaceutical and biotechnology industry. He has worked extensively with major global pharmas and his portfolio has included SmithKline Beecham UK, Glaxo Wellcome UK and Norton Healthcare UK.

During his time at Glaxo, Dr Pang was part of the International Division, where he was responsible for a rich repertoire of activities, such as GMP audits, troubleshooting and project management for the company's worldwide operations. He was also the first project manager appointed for Glaxo China and was heavily involved in the establishment of the first development and manufacturing facility for inhalation systems in Chongqing.

Through his experience in research, development, technology transfer, manufacturing, marketing and general management, Dr Pang has acquired invaluable expertise in the pharmaceutical and biotechnology sector. He now shares his knowledge by sitting on the Boards of various pharmaceutical venture companies in both Hong Kong and mainland China, and is actively involved in technology management and commercialisation enterprises between the East and the West.

Dr Pang played a pivotal role in the signing of a recent licensing agreement between GlaxoSmithKline and Simcere Pharmaceuticals for the rights to manufacture and sell the antiviral influenza treatment zanamivir - the active ingredient in Relenza@reg; - in China, Vietnam, Indonesia, Thailand and all the Least Developed Countries.
Simcere Pharmaceuticals